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Pancreatic cancer is an aggressive disease with an overall 5-year
survival rate of 0.4% (Bramhall et al, 1995). Most patients present
with advanced disease with only 2.6–4% undergoing resection
(Bramhall et al, 1995; NYCRIS, 2000). In advanced disease, the
median survival is only 4–6 months and over 90% of patients are
dead within 1 year. Chemotherapy and radiotherapy are associated
with substantial toxicity and confer only a marginal improvement
in survival (Bakkevold, 1998). 
The matrix metalloproteinases (MMPs) are a family of at least
18 proteolytic enzymes that can be subdivided into four main
groups according to substrate specificity, namely: the collagenases,
stromelysins, gelatinases (type IV collagenases) or membrane-bound
MMPs (MT-MMPs). Collectively, they are able to degrade all
components of the extracellular matrix (Jones et al, 1999). MMP
activity is regulated by four specific tissue inhibitors of the metallo-
proteinases (TIMPs) (Greene et al, 1996; Sellers et al, 1997;
Stetler-Stevenson, 1989; Uria et al, 1994). MMPs have an impor-
tant physiological role in embryonic development (Brenner et al,
1989), bone remodelling (Delaisse and Vaes, 1992) and wound
healing (Wolf et al, 1992), and a major role in pathological
processes including rheumatoid arthritis (Harris, 1990) and cancer
invasion and metastasis (Liotta and Stetler-Stevenson, 1991).
MMP overexpression has been reported in carcinomas of the
ovary (Campo et al, 1992), prostate (Pajouh et al, 1991) and lung
(Brown et al, 1993) and MMP activity correlated with malignant
potential in gastric (Nomura et al, 1995) and colorectal (Mori et al,
1995; Porte et al, 1995) cancer. 
Several studies have indicated that MMP and TIMP expression
are also deranged in pancreatic cancer. Bramhall et al reported
overexpression of MMPs 2 and 3 with TIMP 1 in pancreatic and
ampullary cancers (Bramhall et al, 1996). Subsequent studies
demonstrated that MMPs 2, 7 and 9 and TIMPs 1 and 2 are those
most abundantly expressed in pancreatic cancer tissue with MMP2
and MT-MMP1 co-expressed in 60% of pancreatic cancers
(Bramhall et al, 1997; Gress et al, 1995). TIMP1 expression has
been shown to have an inverse relationship with the presence of
lymph node metastases while increased MMP expression is asso-
ciated with tumour de-differentiation (Bramhall et al, 1994, 1996).
More recently, overexpression of MMPs 2, 7, 8, 9, 12 with reduced
expression of TIMPs 1 and 2 (Jones et al, 2000) has been reported. 
These findings have led to the development of a number of
synthetic matrix metalloproteinase inhibitors (MMP1s). Marimastat
(British Biotech, Oxford, UK) was the first orally bioavailable
broad-spectrum MMPI to enter clinical trials. Structurally, marima-
stat contains a hydroxyamate group that chelates the zinc atom at the
active site of the MMPs, resulting in reversible inhibition of enzyme
activity. Marimastat is active against all major classes of MMPs and
displays an IC50 of 5 nM, 6 nM, 3 nM and 200 nM against collage-
nase, gelatinase 72 kDa and 92 kDa and stromelysin, respectively, at
nanomolar concentrations (Beckett et al, 1996). Phase I studies
demonstrated good tolerability with an elimination half-life of 8–12 h.
A linear relationship was shown between dose and plasma concen-
tration with high plasma levels achieved following a single oral
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doi: 10.1054/ bjoc.2001.2168, available online at http://www.idealibrary.com on  http://www.bjcancer.comdaily dose (Drummond et al, 1995). The aim of this study was to
evaluate the effect and define the tolerability of marimastat in
patients with advanced pancreatic cancer. 
MATERIALS AND METHODS 
Study design 
This was a multicentre open phase II pilot clinical trial to assess the
effect of 28 days’ administration of oral marimastat (British Biotech
Pharmaceuticals Ltd, Oxford, UK) in patients with advanced pancre-
atic cancer with a facility to continue treatment in those patients
with a clinical, serological or radiological ‘response’ to treatment.
Marimastat was administered at a dose of 100 mg b.d., 25 mg o.d. or
10 mg b.d. with the option to reduce the dose in the event of toxicity.
Patients were recruited from five centres throughout the UK between
August 1995 and December 1997. Ethical committee approval was
obtained from the research ethics committee at each investigating
centre prior to study commencement. 
Study objectives 
The aims of this study were: 
1. To evaluate the effect of 28 days’ treatment with oral marimastat
on tumour size measured by computerize tomography (CT),
disease progression was assessed by the level of cancer antigen
CA19-9 and pain, mobility and analgesic use scores 
2. To define the tolerability of marimastat 
3. To assess the tumour response, safety and tolerability in
patients treated beyond 28 days. 
Patient selection 
Patients with radiologically and/or histologically/cytologically
proven advanced pancreatic cancer were considered for study
entry. Inclusion criteria were: (1) patients over 18 years of age; (2)
Eastern Cooperative Oncology Group (ECOG) performance status
of 0–2; (3) estimated survival of at least 3 months and the ability to
take food by mouth. Exclusion criteria included: (1) previous
systemic antineoplastic therapy or radiotherapy within 2 months of
study entry; (2) serum bilirubin level > 100 µ mol/l; (3) serum
albumin level < 25 g/l or positive serology for HIV or HBsAg.
Pre-menopausal females had a negative pregnancy test prior to
study entry. Written informed consent was obtained from all
patients and all patients were commenced on pancreatic enzyme
supplements at study entry. 
Clinical assessment of patients 
Patients entered one of three initial screening periods according to
their presentation: 
1. Patients who had newly diagnosed pancreatic cancer and did
not require stenting or surgery (group 1) were screened 1 week
prior to study entry 
2. Patients with newly diagnosed pancreatic cancer who required
stenting or surgery (group 2) were screened at least 3 weeks
prior to entry 
3. Those with serologically detected recurrent cancer (group 3)
were screened at least 6 weeks prior to study entry, requiring
that the serum CA19-9 level was at least twice the upper limit
of normal on three consecutive occasions or a 20% increase
over a 6-week period. The stage of disease was assessed prior
to study entry according to the American Joint Committee for
Cancer (AJCC) staging system for pancreatic cancer (Cancer of
the Pancreas Task Force, 1981). 
Following study entry, patients were assessed at days 0, 7, 14
and 28, and monthly thereafter in those patients who continued
treatment. Patients who did not continue treatment had a final
assessment on day 56. A full history and clinical examination was
performed 1 week prior to study entry and repeated at day 28 and
monthly on subsequent visits. Concomitant medication, invasive
tests, vital signs (pulse, blood pressure, oral temperature, respira-
tory rate) and a clinical assessment of pain, mobility ECOG score
(Smith et al, 1980) and analgesic use (graded as: 0 = none; 1 = simple
analgesic or non-steroidal anti-inflammatory drugs (NSAIDS);
2 = simple analgesic plus NSAIDS; 3 = moderate analgesia such
as co-proxamol; 4 = opiates < 40 mg morphine (or equivalent)
daily; 5 = opiates > 40 mg but < 100 mg morphine daily; 6 =
opiates > 100 mg morphine daily) was recorded at each visit. 
Routine haematology, biochemistry including C-reactive
protein (CRP) and urinalysis was performed 1 week prior to study
entry, on days 0, 7 and 28 and on each subsequent visit. Serial
electrocardiograms were performed prior to study entry, at day 28
and monthly thereafter. Serum CA19-9 was measured at 6, 4 and 2
weeks before study entry in patients with serologically detected
recurrent disease (group 3), 3 and 2 weeks prior to entry in group 2
and 1 week prior to entry in group one. All patients then had
CA19-9 measurements on days 0, 7, 14 and 28, and then monthly.
Contrast-enhanced spiral CT scanning (CE-CT) was performed
within 2 weeks of study entry, at day 28 then 2, 4, 8 and 12 months
after study entry according to a standardized protocol and reported
by a single independent radiologist in each study centre. Adverse
and serious adverse events were reported immediately to British
Biotech Pharmaceuticals Ltd. 
Definition of clinical response 
A clinical response to treatment was defined as one or more of: (1)
a serum CA19-9 level at day 28 less than or equal to the level at
day 0 (serological response); (2) complete or partial response or
the presence of stable disease on CT scan (radiological response)
using WHO criteria or a pain, mobility and analgesia score that
was no greater at day 28 than at day 0 (clinical response). 
Pharmacokinetic assay 
Samples of venous blood were collected immediately before and 2
hours after the first administration of marimastat on day zero, prior
to the morning dose on days 14 and 28, and monthly thereafter.
Additional samples were taken when any serious adverse event
was suspected and considered to be drug related. Samples were
immediately put on ice and within 30 min of collection, plasma
extracted and stored at –70˚C until analysis was carried out in a
central laboratory. 
Statistical analysis 
Data was analysed using Kaplan–Meier survival curves and the
log rank (Mantel–Cox) statistical test. 
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Patient characteristics 
113 patients with advanced pancreatic cancer were entered into
the study. The median age was 63 (range 32–84) years; 72 (64%)
patients were men. Of the patients included in the study, 28
(25%) patients had stage II disease, 21 (19%) had stage III
disease and 64 (57%) had stage IV disease. The median time
between diagnosis and study entry was 51 days. There were 91
patients (81%) who had previously undergone surgery ranging
from diagnostic laparoscopy to a pancreatico-duodenectomy.
Nine patients (8%) had previously received 5-FU-based
chemotherapy. A total of 64 patients (57%) had a histological
diagnosis of pancreatic ductal adenocarcinoma, 2 (2%) had
adenosquamous carcinomas and 1 (1%) had small cell carcinoma
of the pancreas. No histological confirmation was available in 46
patients (41%). Two patients (2%) had co-existent bladder and
breast cancer, respectively. 
Treatment dosage and duration 
The first nine patients were commenced on marimastat 100 mg
b.d. Early pharmacokinetic data from these patients indicated that
a dose reduction was necessary and a protocol amendment resulted
in a reduction of the dose to 25 mg o.d. A further protocol amend-
ment introduced a third dose of 10 mg b.d. in light of other
ongoing studies on marimastat, which suggested that this was the
optimum dosage regime. A total of 90 patients (80%) completed
the main 28-day study period and 83 (73%) continued treatment.
Median duration of treatment was 78, 60 and 80 days for those
starting treatment at 25 mg o.d. (n = 90), 10 mg b.d. (n = 14) and
100 mg b.d. (n = 9), respectively (range 1–486 days) including
interruptions for tolerability reasons. 
Response to treatment 
Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed
stabilization or a fall in levels during the 28-day study period; 4
patients had received 100 mg b.d. and 19 had received 25 mg o.d.
Of the 83 patients with radiologically assessable disease, 41 (49%)
had stable disease over the initial 28-day study period, while 42
(51%) showed evidence of disease progression. Of 41 patients
with radiologically stable disease, 13 (32%) had stable or reduced
CA19-9 levels, 24 (58%) had a rise in CA19-9 and 4 (10%) had
non-evaluable CA19-9 levels. In those with radiologically
progressive disease, 9 (21%) of 42 patients had stable or reduced
CA19-9 levels, 26 (62%) had a rise in CA19-9 and seven (17%)
had non-evaluable CA19-9 levels. 46 (51%) of 90 patients had a
decrease or stabilization of combined pain, mobility and analgesia
scores from day 0 to day 28 (Table 1). Seven patients (8%) met all
three of requirements to classify them as having a response to
treatment. 
The overall median survival for the 113 patients who entered the
study was 113 days. Survival was 5.9, 4.7 and 3 months for stages
II, III and IV disease respectively (P < 0.04; Figure 1). The median
survival for those with a fall or stabilization of CA19-9 levels was
245 days vs 128 days for those with a rising CA19-9 level
(P = 0.004; Figure 2). Patients were also subdivided into two groups
according to the rate of rise in CA19-9 levels over the 28-day study
period. Group one was made up of those (n = 52) in whom the rate
of CA19-9 was greater than the median and group two included
those (n = 52) in whom CA19-9 levels rose by less than or equal to
the median. Those patients who had a lower rate of rise in CA19-9
had a prolonged median survival time of 183 days compared with
90 days in the remainder of patients (P < 0.003). There was no
statistically significant difference in survival between those
patients with radiologically stable disease compared with those
with progressive disease at 28 days (P = 0.20). 
Pharmacokinetics 
Trough plasma marimastat levels were markedly higher in patients
receiving 100 mg b.d. (mean 321.7 µ g/l, range 133–601 µ g/l) than
those receiving 25 mg o.d. (mean 45.2 µ g/l, range 6–177 µ g/l) or
10 mg b.d. (mean 57.5 µ g/l, range 34–109 µ g/l). Steady state
plasma trough levels were therefore higher in patients with
advanced pancreatic cancer when compared with healthy volun-
teers. Mean plasma trough levels of marimastat following a once
daily dosing regimen, however, were well above the concentration
required to inhibit the major MMPs implicated in tumour invasion. 
Adverse events 
The adverse events reported during the 28-day study period are
shown in Table 2. Over the total study period, musculoskeletal side
effects were increasingly common with arthralgia experienced by
33 (29%) patients, back pain in 10 (9%), joint stiffness in 10 (9%)
and myalgia in 11 (10%). Marimastat treatment was interrupted in
31 patients (27%) who continued treatment beyond 28 days
because of musculoskeletal side effects (Table 3). Serious adverse
events were reported in 104 patients (92%). Serious adverse events
(n = 11) with possible relation to marimastat were reported in 9
patients (8%) including disseminated carcinoma (n = 5), anaemia
(n = 1), diarrhoea (n = 1), nausea (n = 1), jaundice (n = 1), gastro-
intestinal bleeding (n = 1) and myocardial infarction (n = 1). The
reported outcomes in 4 of the 5 cases of disseminated disease and
the patient with myocardial infarction were death. All serious
adverse events were considered to be disease related. 
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Table 1 Change in pain, analgesic use and WHO performance score from
days 0–28 (n = 88) 
Dose Increase No change Decrease 
Change in pain score 
25 mg o.d. 19 40 12 
10 mg o.d. 4 1 4 
100 mg b.d. 2 5 1 
Total 25 (28%) 46 (52%) 17 (19%) 
Change in analgesic use score 
25 mg o.d. 17 47 7 
10 mg o.d. 2 7 0 
100 mg b.d. 0 6 2 
Total 19 (22%) 60 (68%) 9 (10%) 
Change in WHO performance score 
25 mg o.d. 11 55 5 
10 mg o.d. 1 6 2 
100 mg b.d. 0 8 0 
Total 12 (14%) 69 (78%) 7 (8%) DISCUSSION 
The prognosis for patients with pancreatic cancer remains very
poor. There have been many trials on the value of chemotherapy
and radiotherapy in advanced pancreatic cancer but the results
have generally been disappointing. Three out of four randomized,
controlled trials have shown a benefit for chemotherapy compared
to no active treatment or best supportive care. Frey et al found no
survival benefit using a combination of 5-FU and carmustine (Frey
et al, 1980). Mallison et al, however, demonstrated a median
survival of 11 months using a combination of 5-FU, cyclophos-
phamide, methotrexate, vincristine and mitomycin C compared
with 2.2 months for the untreated control group (Mallinson et al,
1980). Studies using 5-FU, doxorubicin and mitomycin C (FAM)
and a combination of 5-FU, folinic acid and etoposide have simi-
larly shown improved survival together with a better quality of life
(Smith et al, 1980; Palmer et al, 1994; Glimelius et al, 1996). More
recently, gemcitabine was shown in a randomized trial to increase
median survival time to 5.7 months compared to 4.4 months in
patients given bolus 5-FU (Burris et al, 1997). Moreover, there
was improved 1 year survival rate with gemcitabine (22% vs 2%)
and a significantly better clinical benefit response. 
The resistance of pancreatic cancer to conventional chemo-
therapy and radiotherapy has driven the development of novel ther-
apeutic agents such as the MMPIs. This study has demonstrated that
marimastat is well absorbed following oral administration with ther-
apeutic plasma levels achieved at a dose of 25 mg o.d. The principal
adverse effect attributable to marimastat was musculoskeletal side
effects that had a variable presentation from joint pain and stiffness,
tendinitis and myalgia. Musculoskeletal side effects were observed
in 14% of patients by 28 days’ treatment but the incidence was
clearly dose and time dependent, with one-third of patients treated
beyond 28 days suffering significant musculoskeletal symptoms
necessitating interruption of treatment and/or dose reduction. The
precise mechanism by which marimastat causes musculoskeletal
side effects is not entirely understood but may be due to disruption
of the normal balance between MMPs and TIMPs within and
around joints. The future development of more specific MMPIs
that affect only the MMPs important in pancreatic cancer progres-
sion, may enable musculoskeletal side effects to be minimized.
Of 76 patients with evaluable cancer antigen levels, 23 (30%)
showed a fall or no change in CA19-9 levels during the 28-day
study period. This ‘serological response’ to treatment was associ-
ated with a significant improvement in survival (245 days vs 128
days) and patients with a lower rate of rise in CA19-9 also had a
prolonged median survival time (183 days vs 90 days). Whilst this
indicates that CA19-9 may be a useful measure of treatment
response, this tumour marker is not ideal. CA19-9 was only
expressed in 75% of patients with pancreatic cancer, and 9 (21%)
of 42 patients with radiologically progressive disease in this study
had stable or reduced CA19-9 levels. These findings demonstrate
the limitations of CA19-9 as a surrogate market of treatment
response. Furthermore improved radiological appearances
following treatment did not translate into improved survival. 
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Table 2 Common adverse events considered to be at least possible related to treatment 
Dose 25 mg o.d. 10 mg b.d. 100 mg b.d. Total 
Days 0–28 
No. treated 90 14 9 113 
With related adverse events 32 (35.6%) 4 (28.6%) 7 (77.8%) 43 (38.1%) 
Musculoskeletal
Arthralgia 9 3 2 14 (12.4%) 
Myalgia 4 2 0 6 ( 5.3%) 
Total study period 
No. treated 90 14 9 113 
With related adverse events 
Musculoskeletal
Arthralgia 22 7 4 33 (29.2%) 
Back pain 7 2 1 10 ( 8.8%) 
Joint stiffness 8 1 1 10 ( 8.8%) 
Myalgia 6 3 2 11 ( 9.7%) 
Pain in limb 6 1 0 7 ( 6.2%) 
Skeletal pain 4 0 2 6 ( 5.3%) 
Gastrointestinal
Dyspepsia 5 1 0 6 ( 5.3%) 
Nausea 7 0 2 9 ( 8.0%) 
Vomiting 6 0 0 6 ( 5.3%) 
Table 3 Patients withdrawn or dose modified due to musculoskeletal side effects 
Dose No.  No.  Patient withdrawn or dose modified (number)
recruited continuing
Days Days Days Days
0–28 56 0–200 0–300
25 mg o.d. 90 67 4 7 19 21 
10 mg o.d. 14 8 1 4 4 5 
100 mg o.d. 9 8 2 4 5 5 Marimastat in advanced pancreatic cancer 1869
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Figure 1 Kaplan–Meier plot demonstrating survival according to stage of disease at study entry.
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Figure 2 Kaplan–Meier plot demonstrating survival according to CA19-9 response to treatment.Median survival time in this study was only 113 days (3.8
months), which may reflect patient selection and bias towards
more advanced disease. Marimastat was associated with stabiliza-
tion or reduction in pain, mobility and analgesic use scores, similar
criteria to those used to assess clinical benefit response in the
gemcitabine study (Burris et al, 1997) in half of the patients 
who entered the study. More recently a pivotal randomized,
controlled study comparing marimastat against gemcitabine in 414
patients with non-resectable pancreatic cancer demonstrated no
difference in survival rate in patients receiving 25 mg b.d. marima-
stat compared with those treated with once weekly i.v. gemc-
itabine at 1000 mg/m2. No difference in quality of life scores or
treatment-related adverse events was demonstrated and this study
is continuing (Bramhall et al, 2001). 
In clinical terms, marimastat appears to be a tumouristatic rather
than a cytotoxic agent. Maximal benefit would be expected
in patients with minimal or microscopic residual disease and
randomized, controlled trials are now in progress to evaluate the
effect of marimastat in the adjuvant setting following resection of
pancreatic cancer. Further development and clinical evaluation of
MMPIs in pancreatic cancer is warranted. 
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